股票购买建议 - 有些股票虽然跌至52周低点，但并不意味着就是买入的时机[1] - 需要谨慎选择，避免购买那些便宜的股票，因为它们可能存在业务问题[2] - 有三只股票在52周低点时值得购买，只需稍加整理和关注即可获得可观回报[3]

First Patient Enrollment in AGILITY Study Begins Investigations of Safety and Effectiveness of BD Vascular Covered Stent for Treatment of PADFRANKLIN LAKES, N.J., March 4, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the investigational device exemption (IDE) study, "AGILITY," which will assess the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Periphera ...

BDX公司表现 - BDX公司在2024财年第一季度中国市场表现疲软，同比下降5.3%，市场占比仅为6.4%[1] - Alaris泵召回导致BDX公司收入和市场份额下降，但预计Alaris泵在2024财年将逐渐恢复市场份额并产生至少2亿美元的收入[5] 预期展望 - BDX公司预计2024财年有望实现5.5%-6.25%的有机收入增长和50个基点的利润率扩张[8]

联邦储备局和AI科技 - 联邦储备局可能会降低利率，推动股市[1] - AI技术的崛起推动科技股上涨[1] 投资市场趋势 - 高估值使得当前市场对投资资本的投放变得困难[2] - 长期投资者仍有很多好的投资机会[2] 优质投资目标 - 选择具有连续25年以上增加股息支付的公司作为投资目标[3] Emerson Electric (NYSE:EMR) - Emerson Electric (NYSE:EMR)是一家工业公司，现在主要专注于工业自动化领域[4] - Emerson Electric (NYSE:EMR)的股票估值相对较低，是长期投资者的不错选择[6] Exxon Mobil (NYSE:XOM) - Exxon Mobil (NYSE:XOM)是一个稳健的蓝筹股，投资者可以通过它参与下一代能源技术[9] - Exxon Mobil (NYSE:XOM)收购了Denbury Resources，成为美国最大的二氧化碳管道所有者[10] IBM (NYSE:IBM) - IBM (NYSE:IBM)在硬件解决方案领域长期占据主导地位，但错过了现代科技解决方案的发展[11] - IBM (NYSE:IBM)持续投资研发，特别是在人工智能和量子计算领域[13] Becton Dickinson (NYSE:BDX) - Becton Dickinson (NYSE:BDX)是一家领先的医疗器械公司，股票估值相对较低[19] - Becton Dickinson (NYSE:BDX)的股票被认为目前处于深度折扣状态，有投资潜力[20] 3M (NYSE:MMM) - 3M (NYSE:MMM)是一家美国制造业巨头，股票估值相对较低，提供丰厚的股息收益[23] NextEra Energy (NYSE:NEE) - NextEra Energy (NYSE:NEE)是美国领先的可再生能源开发商，股票估值被认为处于低点[27] Sherwin-Williams (NYSE:SHW) - Sherwin-Williams (NYSE:SHW)是美国领先的涂料供应商，利用其市场份额和专业涂装商的领先地位赚取高额利润[31]

FRANKLIN LAKES, N.J., Feb. 27, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Dave Hickey has informed the company of his intent to retire from BD, effective July 1. Hickey is currently executive vice president and president of the Life Sciences segment for BD, a position he has held since January 2021. Prior to his current role, Hickey was president of Integrated Diagnostic Solutions from 2019 to 2021, and president of ...

Becton, Dickinson and Company (BDX) , popularly known as BD and Camtech Health, recently announced their strategic collaboration to uplift cervical cancer screening for women in Singapore by providing them the first-ever option to self-collect a sample amidst the privacy of their own home.The partnership is intended to raise the percentage of cervical cancer screening in Singapore, where the present screening rate is less than half of eligible women.Price PerformanceFor the past six months, BDX’s shares hav ...

合作项目介绍 - BD与Camtech Health合作推出新的HPV自我采集样本测试项目，旨在提高新加坡妇女进行宫颈癌筛查的便利性和隐私性[1] - 该项目结合了Camtech Health的HPV自我采集测试和BD Onclarity™ HPV Assay，旨在提高新加坡宫颈癌筛查率，目前新加坡仅有不到一半符合条件的妇女接受筛查[3] 公共卫生挑战 - 通过在家收集样本可以帮助解决无法定期进行宫颈癌筛查的紧急公共卫生挑战，新加坡宫颈癌在全球妇女中排名第四，自2007年至2019年，新加坡所有25-74岁妇女的宫颈癌筛查率下降了17%[5]

医疗行业股票选择建议 - 医疗 - 牙科用品行业的股票选择建议是考虑贝克顿迪金森（BDX）或西方制药服务公司（WST）[1] - 贝克顿迪金森和西方制药服务公司目前的Zacks排名分别为2（买入）和3（持有）[3] - 通过众多估值指标，贝克顿迪金森在价值方面获得B级评分，而西方制药服务公司获得D级评分[8] - 贝克顿迪金森在盈利前景和估值指标上表现优于西方制药服务公司[9]

FRANKLIN LAKES, N.J., Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.The BD Innovates series spotlights BD's innovation, products and pipeline in support of its BD 2025 Strategy, with this installment hig ...

Becton, Dickinson and Company (BDX) , popularly known as BD, is well-poised for growth in the coming quarters, courtesy of its series of product launches over the past few months. The optimism led by a solid first-quarter fiscal 2024 performance and a few regulatory approvals are expected to contribute further. However, macroeconomic concerns and forex volatility persist.Over the past year, this Zacks Rank #3 (Hold) stock has lost 7.2% against the 7.3% rise of the industry and 19.2% growth of the S&P 500.Th ...